BRAF and thyroid gland carcinoma: Conversely, BRAF V600E mutation in thyroid cancer did not show a marked difference in MAPK pathway activation compared to WT (median MPASs: = 0.05 and −0.53, respectively, p = 0.59) (Figure 2).